Despite significant advances in medical science, Tuberculosis (TB) remains a global health challenge. Early and accurate diagnosis is critical to control its spread and improve patient outcomes. This article provides a comprehensive review of modern TB diagnostic techniques.
PCR-based tests, such as the Xpert MTB/RIF assay, have revolutionized TB diagnostics. They offer rapid, sensitive, and specific detection of Mycobacterium tuberculosis and rifampicin resistance. The WHO recommends these tests as initial diagnostics in adults suspected of having MDR-TB or HIV-associated TB.
Interferon-gamma release assays (IGRAs) and tuberculin skin tests (TST) are the mainstay of latent TB diagnostics. IGRAs, which measure the immune response to TB-specific antigens, are more specific than TST and are not affected by prior BCG vaccination. However, neither test can distinguish between latent infection and active disease.
Chest radiography remains a vital tool in TB diagnosis, especially in resource-limited settings. It can provide rapid results, but its sensitivity and specificity are variable. Computed tomography (CT) and magnetic resonance imaging (MRI) offer better resolution and can detect extrapulmonary TB, but their high cost and limited availability restrict their use.
Culture remains the gold standard for TB diagnosis, providing definitive evidence of infection. It allows drug susceptibility testing, but it is slow and requires sophisticated laboratories. Newer techniques, such as line probe assays, offer faster results and simultaneous detection of drug resistance.
In conclusion, an array of diagnostic tools is available for TB, each with its strengths and limitations. Rapid molecular tests have improved the speed and accuracy of diagnosis, but culture remains the gold standard. The choice of diagnostic approach should be tailored to the patient's clinical presentation and the resources available.
1.
Injecting PD-1 Drug Directly Into Oral Precancers Shrinks Lesions
2.
Sevabertinib Approved for First-Line Mutated NSCLC
3.
After three years, responses to mounetuzumab in follicular lymphoma are still stable.
4.
FDA Bans Red Dye No. 3 From Foods, Ingested Drugs
5.
AI can identify women at risk of breast cancer years in advance: Study
1.
Revolutionizing Cancer Treatment: Advances in Immunotherapy and Cell Therapy
2.
Pediatric Tumor Microenvironment Evolution: Mechanisms, Clinical Impact, and Therapeutic Implications
3.
Hematopoietic Stem Cell Activity Biomarkers in Aging
4.
Bone-Marrow Immune Cell Competition: Mechanisms, Clinical Implications, and Emerging Therapeutic Perspectives
5.
The Truth About TAR Syndrome: Understanding the Rare Genetic Disorder
1.
International Conference on Innovations in Critical Care for Oncology and Cardiology
2.
International Conference on Oncology, Cardiology and Critical Care Policy
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
1.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VIII
2.
A New Era in Managing Cancer-Associated Thrombosis
3.
Emerging Concepts in Hematology
4.
The Reign of the CROWN Trial and the Dawn of a New Era in Frontline Management- Further Discussion
5.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion III
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation